Table 4.
Cure rates accordingly to previous therapeutic failures.
| No. of Failures | Therapy | No. | PP | 95% CI | ITT | 95% CI |
|---|---|---|---|---|---|---|
| 1 (415 pts) | Sequential | 67 | 98.4 | 91.5–99.7 | 92.5 | 83.7–96.8 |
| Levofloxacin-based | 221 | 88.5 | 83.2−92.2 | 79.7 | 73.8–84.4 | |
| Rifabutin-based | 109 | 89.0 | 81.0–93.9 | 74.3 | 65.4–81.6 | |
| Pylera® | 18 | 94.1 | 73.0–99.0 | 88.9 | 67.2–96.9 | |
| 2 (310 pts) | Sequential | 29 | 84.5 * | 71.0–96.0 | 79.3 | 71.6–91.1 |
| Levofloxacin-based | 132 | 88.1 | 81.3–92.6 | 84.1 | 76.9–89.3 | |
| Rifabutin-based | 129 | 82.2 | 74.3–88.0 | 75.2 | 67.1–81.8 | |
| Pylera® | 20 | 94.7 | 75.3–99.1 | 90.0 | 69.9–97.2 | |
| ≥3 (312 pts) | Sequential | 18 | 81.2 | 57.0–93.4 | 72.2 | 49.1–87.5 |
| Levofloxacin-based | 63 | 77.1 | 65.1–85.8 | 74.6 | 72.7–83.7 | |
| Rifabutin-based | 216 | 82.2 | 76.3–86.8 | 76.9 | 70.8–82.0 | |
| Pylera® | 15 | 80.0 * | 54.8–92.9 | 80.0 | 54.8–92.9 |
* Sequential therapy had a statistically significant (P < 0.05) decrease in eradication rates if used as third line therapy. Pylera® had a statistically significant decrease in eradication rates if used as fourth line therapy. Pts: patients. PP: per protocol analysis. ITT: intention to treat analysis.